Shopping Cart
- Remove All
- Your shopping cart is currently empty
Sonrotoclax is a potent, orally active inhibitor of Bcl2, demonstrating effective cell-killing activity against a range of lymphoma and leukemia cell lines [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $372 | 7-10 days |
Description | Sonrotoclax is a potent, orally active inhibitor of Bcl2, demonstrating effective cell-killing activity against a range of lymphoma and leukemia cell lines [1]. |
In vivo | In Female NCG mice with acute lymphoblastic leukemia ( ALL ) xenografts, Sonrotoclax ( 5,15,50 mg / kg ; oral administration ; daily, for 42 days ) can inhibit tumor growth in a dose-dependent manner[1]. |
Alias | BGB 11417 |
Molecular Weight | 890.10 |
Formula | C49H59N7O7S |
Cas No. | 2383086-06-2 |
Smiles | CC(C1=C(C=CC=C1)[C@H]2N(CCC2)C3CC4(CCN(C5=CC(OC6=CN=C(NC=C7)C7=C6)=C(C=C5)C(NS(=O)(C8=CC([N+]([O-])=O)=C(C=C8)NC[C@@H]9CC[C@@](O)(CC9)C)=O)=O)CC4)C3)C |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
Solubility Information | DMSO: 80 mg/mL (89.88 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.